Beyond Air® Appoints Dan Moorhead as Chief Financial Officer

Core Insights - Beyond Air, Inc. has appointed Dan Moorhead as Chief Financial Officer, effective January 5, 2026, succeeding Duke Dewrell, who served as interim CFO since November 2025 [1][2] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to enhance patient care, particularly for respiratory illnesses, neurological disorders, and solid tumors [5][6] - The company has received FDA approval and CE Mark for its first system, LungFit PH, aimed at treating term and near-term neonates with hypoxic respiratory failure [5] Leadership Appointment - Dan Moorhead brings over 20 years of finance leadership experience, having previously served as CFO of Zynex, Inc., where he supported significant commercial expansion [3] - Moorhead expressed enthusiasm about joining Beyond Air at a critical time, particularly with the upcoming FDA approval of the second generation LungFit PH and its commercial launch [2][3] Inducement Stock Option - Upon his appointment, Moorhead was granted an inducement stock option for 70,000 shares of the company's common stock, exercisable at the last reported sale price on December 31, 2025 [4] - The stock option has a ten-year term and will vest over four years, with 25% vesting on the first anniversary and the remainder in three equal installments [4] Product Development - Beyond Air is advancing its LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [5][6] - The company is also collaborating with The Hebrew University of Jerusalem on a pre-clinical program for treating autism spectrum disorder and other neurological disorders [6]